Mineralys Therapeutics (MLYS) reported a Q2 loss late Tuesday of $2.85 per diluted share, widening from a loss of $0.66 a year earlier.
Analysts polled by FactSet expected a loss of $0.55.
As expected, no revenue was reported for the quarter ended June 30.
Cash and cash equivalents as of June 30 were $661.4 million, which is expected to fund operations into 2028, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.